CA3041531A1 - In vivo chemoselection with low dose thioguanine - Google Patents

In vivo chemoselection with low dose thioguanine Download PDF

Info

Publication number
CA3041531A1
CA3041531A1 CA3041531A CA3041531A CA3041531A1 CA 3041531 A1 CA3041531 A1 CA 3041531A1 CA 3041531 A CA3041531 A CA 3041531A CA 3041531 A CA3041531 A CA 3041531A CA 3041531 A1 CA3041531 A1 CA 3041531A1
Authority
CA
Canada
Prior art keywords
day
amount
administered
weeks
doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3041531A
Other languages
English (en)
French (fr)
Inventor
Jeffrey S. Bartlett
Louis Randall Breton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring Gene Therapy Inc
Original Assignee
Calimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calimmune Inc filed Critical Calimmune Inc
Publication of CA3041531A1 publication Critical patent/CA3041531A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA3041531A 2016-11-18 2017-11-17 In vivo chemoselection with low dose thioguanine Pending CA3041531A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423794P 2016-11-18 2016-11-18
US62/423,794 2016-11-18
PCT/US2017/062127 WO2018094126A1 (en) 2016-11-18 2017-11-17 In vivo chemoselection with low dose thioguanine

Publications (1)

Publication Number Publication Date
CA3041531A1 true CA3041531A1 (en) 2018-05-24

Family

ID=60915599

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3041531A Pending CA3041531A1 (en) 2016-11-18 2017-11-17 In vivo chemoselection with low dose thioguanine

Country Status (8)

Country Link
US (2) US20180140606A1 (https=)
EP (1) EP3541392A1 (https=)
JP (2) JP2019535737A (https=)
KR (1) KR20190086497A (https=)
CN (1) CN109963566A (https=)
AU (1) AU2017363154A1 (https=)
CA (1) CA3041531A1 (https=)
WO (1) WO2018094126A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111343996A (zh) 2017-07-18 2020-06-26 卡利门股份有限公司 用于选择供体修饰细胞的可调节开关

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012245269B2 (en) * 2011-04-20 2016-09-29 The Regents Of The University Of California Method for combined conditioning and chemoselection in a single cycle

Also Published As

Publication number Publication date
JP2023025149A (ja) 2023-02-21
AU2017363154A1 (en) 2019-05-16
EP3541392A1 (en) 2019-09-25
US20190269687A1 (en) 2019-09-05
KR20190086497A (ko) 2019-07-22
JP2019535737A (ja) 2019-12-12
WO2018094126A1 (en) 2018-05-24
CN109963566A (zh) 2019-07-02
US20180140606A1 (en) 2018-05-24
AU2017363154A9 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
Evans et al. Immucillins in infectious diseases
TWI615143B (zh) 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
CN1309421C (zh) 诸如雷帕霉素和吉西他滨或氟尿嘧啶的抗肿瘤联合
CN107921032B (zh) 用于治疗神经学疾病或病症的vmat2抑制剂
EP3577124B1 (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
JP6450323B2 (ja) デオキシウリジントリホスファターゼ阻害剤
JP2024514825A (ja) 抗ウイルス剤としてのヌクレオシド及びヌクレオチドアナログ
TWI631949B (zh) 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
TWI674897B (zh) 藉二氫吡并吡化合物組合療法的癌症治療方法
CA2512319A1 (en) Compositions and methods for combination antiviral therapy
Parker et al. Purine metabolism in Mycobacterium tuberculosis as a target for drug development
Pinna et al. A new ethyladenine antagonist of adenosine A2A receptors: Behavioral and biochemical characterization as an antiparkinsonian drug
JP2025061603A (ja) 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用
US20190269687A1 (en) In Vivo Chemoselection with Low Dose Thioguanine
De Clercq The magic of a methyl group: Biochemistry at the service of medicine
HK40003311A (en) In vivo chemoselection with low dose thioguanine
Dagen et al. Inhibitors of purine and pyrimidine pathways
WO1993018776A1 (en) Combinations of compounds having antiviral activity
Wu et al. Radiolabeled nucleosides for predicting and monitoring the cancer therapeutic efficacy of chemodrugs
GUDMUNDSSON et al. Benzimidazole ribonucleosides: Novel drug candidates for the prevention and treatment of cytomegalovirus diseases
Sherman Salvage of purines
HK40087531A (zh) Janus激酶抑制剂和端粒酶抑制剂用於治疗骨髓增殖性肿瘤的用途
PL249392B1 (pl) Inhibitor enzymu szlaku zapasowego nukleotydów purynowych komórki H. pylori do zastosowania w leczeniu infekcji H. pylori i/lub leczeniu lub profilaktyce choroby, której patogeneza związana jest z infekcją H. pylori
Van Camp Decitabine (Dacogen): A DNA methyltransferace inhibitor for cancer
Curbo et al. 9-β-D-Arabinofuranosylguanine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20221116